Clinical trials: Bacterial Vaginosis (BV)
Bacterial Vaginosis
Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis
This research study is being done to compare the safety and efficacy of GDC-229 (test drug) against the currently marketed reference drug (metronidazole 0.75% vaginal gel) and to establish that these two drugs work better than…
- Trial name
- NCT03091777
- Testing
- GDC-229, Metronidazole Vaginal Gel 0.75%
- Where
- United States
- Volunteers
- 871 people
- Sponsor
- Balmoral Medical company
Bacterial Vaginosis
Treatment of Bacterial Vaginosis (BV) With Tinidazole
We are trying to determine if treatment of bacterial vaginosis with tinidazole is better than treatment with metronidazole
- Trial name
- NCT00334633
- Testing
- tinidazole, metronidazole
- Where
- United States
- Volunteers
- 593 people
- Sponsor
- University of Alabama at Birmingham
Bacterial Vaginosis
Suppression Of Bacterial Vaginosis (BV) [SUBVert]
A Phase II randomized, double-blind, placebo-controlled study screening approximately 600 adult females, aged 18-55, with a goal to enroll approximately 250 participants to achieve 200 evaluable participants at the test of cure…
- Trial name
- NCT03930745
- Testing
- TOL-463
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Bacterial Vaginosis
Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study
This investigation assessed the effects of asymptomatic BV on daily genital tract shedding of HSV-2 by determining shedding frequency before and after treatment of asymptomatic BV.
- Trial name
- MASH (NCT00464542)
- Testing
- Metronidazole
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Bacterial Vaginosis
Dose Ranging Study of SPL7013 Gel for Treatment of Bacterial Vaginosis (BV)
The purpose of this study is to determine the efficacy of SPL7013 Gel in the treatment of bacterial vaginosis.
- Trial name
- NCT01201057
- Testing
- 0.5% SPL7013 Gel, 1.0% SPL7013 Gel, 3.0% SPL7013 Gel
- Where
- 5 sites in United States
- Volunteers
- 132 people
- Sponsor
- Starpharma Pty Ltd
Bacterial Vaginosis
A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis
The primary objective of the study is to assess the efficacy of 1% SPL7013 Gel compared to placebo gel for the treatment of bacterial vaginosis (BV).
- Trial name
- NCT01577238
- Testing
- 1% SPL7013 Gel
- Volunteers
- 250 people
- Sponsor
- Starpharma Pty Ltd
Bacterial Vaginosis
Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)
A double-blind, phase 3 study to determine the efficacy of SPL7013 Gel when administered on alternate days for 16 weeks, compared to placebo gel in preventing the recurrence of BV in women with a history of recurrent BV.
- Trial name
- NCT02237950
- Testing
- Metronidazole oral tablets 500mg, 1% SPL7013 Gel
- Where
- 45 sites in United States, Canada and 1 more
- Volunteers
- 586 people
- Sponsor
- Starpharma Pty Ltd
Bacterial Vaginosis
A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis
The primary objective of the study is to assess the efficacy of 1% SPL7013 Gel compared to placebo gel for the treatment of bacterial vaginosis (BV).
- Trial name
- NCT01577537
- Testing
- 1% SPL7013 Gel
- Volunteers
- 251 people
- Sponsor
- Starpharma Pty Ltd
Recurrent Bacterial Vaginosis
Randomized Controlled Trial of Treatment of Male Partners of Women With BV
Male partners of womoen with recurrent bacteria vaginosis are randomized to treatment with metronidazole or placebo to compare the rates of recurrent BV in the women
- Trial name
- NCT02209519
- Testing
- Metronidazole (male partner), Placeob (male partner)
- Where
- United States
- Volunteers
- 214 people
- Sponsor
- University of Alabama at Birmingham